Lymphopenia induced by etanercept

Annals of Allergy, Asthma and Immunology

Volumn 112, Issue 3, 2014, Pages 262-263

  Pepper, Amber N ^a   Talreja, Neetu ^a   Cowan, Gregory M ^a   Glaum, Mark C ^a   Lockey, Richard F ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; IMMUNOGLOBULIN G; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; CASE REPORT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE REACTION; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MIDDLE AGED; NEUROPATHY; PATIENT COUNSELING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LUNG DISEASES; LYMPHOPENIA; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894532551     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2013.12.019     Document Type: Article

References (10)

1. R. Yazdani, H. Simpson, and V.V. Kaushik Incidence of cytopaenias with anti-TNF therapy Rheumatology 46 suppl 1 2007 i33
2. C. Wenham, K. Gadsby, and C. Deighton Three significant cases of neutropenia with etanercept Rheumatology 47 2008 376 377
3. V.F. Azevedo, M.B. Silva, D.K. Marinello, F.D. Santos, and G.B. Silva Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review Rev Bras Reumatol 52 2012 110 112
4. B. Szalay, L. Acs, B. Vásárhelyi, L. Kovács, and A. Balog Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy J Clin Rheumatol 17 2011 377 379
5. M. Haroon, M. Daly, and S. Harney Re-challenge with etanercept in patients with etanercept-induced neutropenia Clin Rheumatol 31 2012 151 155
6. R. Hastings, T. Ding, and S. Butt et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy Arthritis Care Res 62 2010 764 769
7. F. Coury, C. Ferraro-Peyret, and S. Le Cam et al. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy Clin Exp Rheumatol 26 2008 234 239
8. T. Ding, J. Ledingham, and R. Luqmani et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies Rheumatology 49 2010 2217 2219
9. K.G. Saag, G.G. Teng, and N.M. Patkar et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 2008 762 784
10. J.A. Singh, D.E. Furst, and A. Bharat et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res 64 2012 625 639